Skip to main content
      RT @MeralElRamahiMD: Coding 101 pearls! Under coding is considered fraud per Dr. Vladimir Liarski @vladml @RheumNow #ACR

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Coding 101 pearls! Under coding is considered fraud per Dr. Vladimir Liarski @vladml @RheumNow #ACR20 https://t.co/idkPJeUzvu
      RT @jrheum: Taking a break at the #ACR20? Visit https://t.co/KmscOUu8MO and access our online library of the the latest

      The Journal of Rheumatology jrheum

      4 years ago
      Taking a break at the #ACR20? Visit https://t.co/KmscOUu8MO and access our online library of the the latest video abstracts, as well as extensive author interviews hosted by our editor. https://t.co/iRxroN2YWN
      RT @Janetbirdope: Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not

      Janet Pope Janetbirdope

      4 years ago
      Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O
      RT @Janetbirdope: Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data

      Janet Pope Janetbirdope

      4 years ago
      Are SpA response differences part of disease subsets or drug pharmacodynamics or both or neither? Data from COASTW & MEASURE2 @RheumNow #ACR2020 @CRASCRRheum https://t.co/GsFjZuZRvI
      RT @DrPetryna: @RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA lev

      Olga Petryna DrPetryna

      4 years ago
      @RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
      RT @Janetbirdope: I admit I don’t get it. Warfarin has more cartilage loss than DOACs. Is this real or a reflection of

      Janet Pope Janetbirdope

      4 years ago
      I admit I don’t get it. Warfarin has more cartilage loss than DOACs. Is this real or a reflection of diff access to cheap vs expensive meds?Duration response seen. Need RCT or subanalysis of a fib RCTs. #bestinclass great trainee plenary #934 @RheumNow @CRASCRRheum #ACR20 https://t.co/Eg1ymtDdmI
      RT @bella_mehta: Billing and coding is important! Trying to learn more at #ACR20 #3S017😖 Common pitfalls noted here @

      Bella Mehta bella_mehta

      4 years ago
      Billing and coding is important! Trying to learn more at #ACR20 #3S017😖 Common pitfalls noted here @RheumNow New 2021 EM CPT coding comin soon- so things will have to be relearned..:( [PE will go away from billing requirements??]😐 https://t.co/GeBxQ0lb8l
      RT @uptoTate: Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the

      Dr. Rachel Tate uptoTate

      4 years ago
      Dr. M. Dubreuil shares a beautiful slide describing the asynchrony between the goal and the reality in the classification of axSpA. Do you think it’s time to change our nomenclature and classification criteria? #ACR20 @RheumNow https://t.co/YJcvLKnyFy
      RT @uptoTate: Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS cri

      Dr. Rachel Tate uptoTate

      4 years ago
      Dr. J. Kay reviews ICD11 classification codes for medical claims for diagnosing SpA which reviews ASAS criteria. This likely won’t be adopted in the US for several years. #ACR20 ⁦@RheumNow⁩ https://t.co/oDhs1EHSTP
      RT @Janetbirdope: Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX bett

      Janet Pope Janetbirdope

      4 years ago
      Is it time to change RA EULAR guidelines to reflect what we do? SEAM RCT showed withdrawal of MTX better than D/C etanercept in controlled RA. ETN alone =ETN+MTX. I vote to d/c the Rx that failed or by pt preference! Abstr#939 @RheumNow #ACR20 https://t.co/l9TNM3Gt0e
      RT @uptoTate: Dr. V. Liarski reviews 11 pearls for billing and coding in #ACR20 @RheumNow my favorite takeaway is #11 go

      Dr. Rachel Tate uptoTate

      4 years ago
      Dr. V. Liarski reviews 11 pearls for billing and coding in #ACR20 @RheumNow my favorite takeaway is #11 good billing does not equal good medical practice and vice versa! https://t.co/M7yMMoFwwD
      RT @DrPetryna: @RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median L

      Olga Petryna DrPetryna

      4 years ago
      @RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC
      RT @uptoTate: Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was

      Dr. Rachel Tate uptoTate

      4 years ago
      Do you know Walter Bauer, MD #ACR20? Well, I didn't either! Dr. M. Weinblatt taught me that Dr. Bauer was an important US rheumatologist who did NOT believe AS was a separate disease entity from RA! It wasn't until his death that the college recognized both separately! @RheumNow
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzy

      Dr. John Cush RheumNow

      4 years ago
      RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.